A new treatment to protect babies against a common and potentially dangerous winter virus has been approved by the UK regulator.
The single antibody shot helps stop infants getting chest infections, such as pneumonia, for about six months.
A large study has now begun to find out whether nirsevimab should be offered to all babies in the UK.
Respiratory syncytial virus (RSV) is the main reason children under five end up in hospital.
Other treatments for RSV already exist and trials of a vaccine have also shown promise.